For Immediate ReleaseChicago, IL – January 30, 2026 – Stocks in this week’s article are Nexa Resources NEXA, Harmony Biosciences HRMY, Commercial Metals CMC and Suzano SUZ.4 GARP Stocks with Attractive PEG Ratios & Strong Growth OutlooksIn the equity market, investments need to be prudently hedged to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether one should resort to a value strategy that seeks discounted stocks or opt for growth investing in time ...

Core Viewpoint - Harmony Biosciences is entering 2026 with significant momentum driven by three key factors: strong performance of WAKIX, a robust late-stage pipeline, and a strong financial profile [3][4]. Group 1: WAKIX Performance - WAKIX has shown five years of consecutive growth and profitability, with guidance for 2026 indicating over $1 billion in net revenue, positioning it to achieve blockbuster status this year [3]. Group 2: Late-Stage Pipeline - The company has five Phase III programs in the clinic targeting five distinct CNS indications, which are expected to provide multiple catalysts in the coming years [4]. Group 3: Financial Profile - Harmony Biosciences is characterized by a strong financial profile, indicating profitability and a solid foundation for future growth [4].

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Event**: 44th JPM Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Core Focus**: Central Nervous System (CNS) disorders, particularly narcolepsy and related conditions - **Product Highlight**: WAKIX, a treatment for narcolepsy, is on track to achieve blockbuster status in 2026 with projected net revenue exceeding $1 billion Core Points and Arguments 1. **Momentum and Growth**: Harmony enters 2026 with significant momentum driven by three key factors: WAKIX performance, a robust late-stage pipeline, and a strong financial profile [2][3] 2. **WAKIX Performance**: WAKIX has shown five years of consecutive growth and profitability, with 2025 net revenue reported at $868 million, exceeding guidance [9][41] 3. **Pipeline Development**: Five phase three programs are advancing towards distinct CNS indications, setting up multiple catalysts for growth in the coming years [2][24] 4. **Pitolisant Franchise Expansion**: The introduction of Pitolisant GR (gastro-resistant formulation) and Pitolisant HD (high-dose formulation) aims to address unmet patient needs and expand the franchise [4][13] 5. **Market Opportunity**: There are approximately 80,000 diagnosed narcolepsy patients in the US, with an additional 90,000 undiagnosed, indicating significant growth potential for WAKIX [10][42] 6. **Commercial Strategy**: Harmony has improved its commercial operations, achieving broad formulary access (80% of lives covered) and enhancing patient support systems [11][27] 7. **Regulatory Milestones**: Anticipated NDA submission for Pitolisant GR in Q2 2026, with a PDUFA date expected in Q1 2027 [30][37] 8. **Financial Health**: Harmony maintains a strong balance sheet with over $770 million in cash, allowing for continued investment in pipeline development and business growth [44][45] Additional Important Insights - **Patient-Centric Approach**: The company emphasizes the importance of addressing patient needs, particularly in narcolepsy and related disorders, through innovative product formulations [4][14] - **Unique Product Profiles**: The differentiated profiles of Pitolisant formulations are expected to enhance clinical utility and market competitiveness [6][39] - **Future Catalysts**: Anticipated data readouts from ongoing trials in 2027 and 2028 for various CNS indications, including Prader-Willi syndrome and epilepsy programs [21][20] - **Business Development Focus**: Harmony is actively seeking strategic opportunities to expand its portfolio in the CNS space, particularly in orphan and rare diseases [44][45] This summary encapsulates the key points discussed during the conference, highlighting Harmony Biosciences' strategic direction, product pipeline, and market opportunities within the CNS industry.

Financial Performance and Growth - Harmony Biosciences anticipates net revenue between $1 billion and $1.04 billion for 2026[16] - The company's revenue has grown consistently year-over-year, with $714.7 million in 2024, $868 million in 2025, and projected growth into 2026[52] - WAKIX net revenue has shown significant growth from $160 million in 2020 to over $1 billion projected for 2026[15] Pitolisant Franchise Strategy - The company is focused on growing the WAKIX franchise, extending it with Pitolisant GR, and expanding it with Pitolisant HD[8] - Pitolisant GR has the potential to extend the pitolisant franchise with utility patents filed to 2044[9] - Pitolisant HD has the potential to expand the pitolisant patient base into new indications[9] Pipeline Development - A Phase 1 clinical PK data for BP1.15205, a potential best-in-class Orexin 2 Receptor (OX2R) Agonist, is anticipated in mid-2026[42] - Topline data from ongoing global Phase 3 trials for EPX-100 in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) are anticipated in 1H 2027[45, 47] - The company submitted an NDA for Pitolisant GR in Q2 2026, with an anticipated PDUFA date in Q1 2027[31] Market Opportunity - There are approximately 170,000 people living with narcolepsy in the U S, with over 50% undiagnosed[22]

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Key Product**: WAKIX, a treatment for narcolepsy Industry Insights - **Market Size**: Approximately 80,000 diagnosed narcolepsy patients, with an additional 80,000 to 90,000 undiagnosed patients, indicating significant growth potential in the narcolepsy treatment market [10][10] - **Polypharmacy**: The narcolepsy market is characterized by high polypharmacy, with patients often on multiple therapies [8][8] Key Product Performance - **WAKIX Growth**: - Achieved a record increase of 500 patients in Q3, the highest since launch, following a steady growth pattern of adding 100 to 400 patients per quarter over the last six years [5][5] - Currently, 8,100 patients are on WAKIX therapy, indicating substantial room for growth in a market of 80,000 diagnosed patients [10][10] Competitive Landscape - **Oxybate Generics**: Anticipation of multiple Xyrem generics entering the market next year, which may lower costs for oxybate therapy but is expected to have limited impact on WAKIX due to its unique non-scheduled status [22][22] - **Orexin Agonists**: - Takeda's orexin agonist is expected to launch in late 2026, but the impact on WAKIX is anticipated to be small initially, with a gradual effect over time [28][28] - WAKIX is perceived as well-tolerated and effective, maintaining a strong position among healthcare providers [27][27] Future Developments - **Orexin Agonist Program**: Harmony has initiated a phase one PK/PD program for its own orexin agonist, with plans to accelerate to phase two and three based on initial data [30][30] - **Next-Gen Pitolisant**: - A gastro-resistant formulation of Pitolisant (Pitolisant GR) is on track for NDA submission in early 2027, aiming to improve patient adherence and outcomes [41][41] - A high-dose formulation (Pitolisant HD) is also in development, with phase three trials for narcolepsy and idiopathic hypersomnia set to begin [44][44] Clinical Insights - **Fatigue Management**: Fatigue, a common issue in narcolepsy, will be a secondary outcome in clinical trials for both narcolepsy and idiopathic hypersomnia, aiming to differentiate the product further [45][45] - **Clemizole for Pediatric Epilepsies**: Harmony is in phase three trials for clemizole hydrochloride in Dravet and Lennox-Gastaut syndromes, with top-line data expected in late 2026 [50][50] Conclusion - Harmony Biosciences is positioned for growth in the narcolepsy market with WAKIX, while also exploring new opportunities with orexin agonists and next-generation formulations of Pitolisant. The company is actively addressing unmet medical needs in both narcolepsy and pediatric epilepsy markets.

Core Insights - Harmony Biosciences has initiated a Phase 1 clinical trial for BP1.15205, a potential best-in-class orexin 2 receptor agonist aimed at treating central disorders of hypersomnolence, including narcolepsy and idiopathic hypersomnia [1][2] - The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BP1.15205, with topline data expected in 2026 [1][2] - The drug has shown high potency and selectivity in preclinical studies, with a favorable safety profile and potential for once-daily dosing [1][2] Company Overview - Harmony Biosciences is focused on developing innovative therapies for rare neurological diseases, emphasizing a commitment to patients with unmet medical needs [6] - The company was established in 2017 and is headquartered in Plymouth Meeting, Pennsylvania [6] Product Development - BP1.15205 is part of Harmony's orexin program, which aims to expand its sleep-wake franchise and provide additional treatment options for patients with narcolepsy and hypersomnolence disorders [3] - The Phase 1 trial is being conducted by Bioprojet Pharma in the European Union, with Harmony holding an exclusive licensing agreement for development and commercialization in the U.S. and Latin America [3] Market Context - Narcolepsy affects approximately 170,000 Americans, characterized by excessive daytime sleepiness and cataplexy, with a significant impact on daily functioning [4] - Idiopathic hypersomnia is another debilitating disorder marked by excessive daytime sleepiness despite adequate sleep, affecting patients' cognitive functions [5]

Financial Performance - Q3 2025 net product revenue reached $239.5 million, a 29% increase year-over-year compared to $186.0 million in Q3 2024[6, 36] - The company raised its full-year 2025 revenue guidance to $845 million - $865 million[6] - Non-GAAP adjusted net income increased by 11% from $57.3 million in Q3 2024 to $63.5 million in Q3 2025[36] - Cash, cash equivalents, and investments increased to $778.4 million in Q3 2025, a 54% increase compared to $504.7 million in Q3 2024[36, 38] WAKIX Performance - WAKIX average patients reached 8,100[11] - Approximately 500 average patient additions, representing the highest quarterly increase since launch[11] - Strong payer coverage of WAKIX at >80% of lives[11] Pipeline Development - The company plans to initiate Phase 3 registrational trials for Pitolisant HD in narcolepsy and IH in Q4 2025[20, 21] - Topline data from the pivotal bioequivalence study of Pitolisant GR is expected in Q4 2025[25, 33] - Phase 3 registrational trials are ongoing for EPX-100 in Dravet Syndrome (ARGUS study) and Lennox-Gastaut Syndrome (LIGHTHOUSE study), with topline data anticipated in 2026[19, 31, 33] - The Phase 3 RECONNECT study for ZYN002 in Fragile X Syndrome (FXS) did not meet the primary endpoint due to a higher-than-expected placebo response rate, and a review of the full data set is ongoing[19, 28]

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is recognized as a promising growth stock by analysts, with a Buy rating reiterated by Truist Financial on October 24 [1] - The company reported strong Q3 2025 performance for its WAKIX product, generating approximately $239 million in revenue, marking a 29% year-over-year growth [2] - The increase in revenue was attributed to a record rise in the average number of patients, which grew by 500 to reach 8,100 during the quarter [2] - Harmony has also raised its revenue guidance for 2025 to a range of $845 million to $865 million, up from the previous range of $820 million to $860 million [3] - The company focuses on developing and commercializing therapies for rare neurological diseases and other unmet medical needs [3]

Core Insights - Harmony Biosciences announced strong preliminary results for Q3 2025, driven by the performance of WAKIX, which shows significant market potential [1][6] - The company raised its 2025 revenue guidance to a range of $845 million to $865 million, up from the previous range of $820 million to $860 million [6] Financial Performance - WAKIX generated approximately $239 million in net revenue for Q3 2025, reflecting a 29% year-over-year growth [6] - The average number of patients using WAKIX increased by approximately 500, reaching 8,100 patients in Q3 2025, indicating a strong trajectory towards potential blockbuster status [6] Upcoming Events - Harmony will report full Q3 2025 financial results on November 4, 2025, and will host a conference call at 8:30 a.m. ET on the same day [2][3]

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is identified as a promising low-priced growth stock, with analysts at H.C. Wainwright maintaining a 'Buy' rating but lowering the price target from $70 to $55, indicating a potential upside of nearly 100% [1] - The company faced a setback with its Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint for treating Fragile X syndrome, attributed to a higher-than-expected placebo response [2] - Despite halting the development of ZYN002 for 22q11.2 deletion syndrome, Harmony continues to demonstrate commercial strength through its product WAKIX and maintains a solid balance sheet, supporting ongoing R&D and business development efforts [3] Company Overview - Harmony Biosciences Holdings, Inc. is a Pennsylvania-based pharmaceutical company focused on therapies for rare and neurological diseases, founded in 2017 with an emphasis on empathy and innovation [4]